Literature DB >> 10646108

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

L C Hofbauer1, S Khosla, C R Dunstan, D L Lacey, W J Boyle, B L Riggs.   

Abstract

Although multiple hormones and cytokines regulate various aspects of osteoclast formation, the final two effectors are osteoprotegerin ligand (OPG-L)/osteoclast differentiation factor (ODF), a recently cloned member of the tumor necrosis factor superfamily, and macrophage colony-stimulating factor. OPG-L/ODF is produced by osteoblast lineage cells and exerts its biological effects through binding to its receptor, osteoclast differentiation and activation receptor (ODAR)/receptor activator of NF-kappa B (RANK), on osteoclast lineage cells, in either a soluble or a membrane-bound form, the latter of which requires cell-to-cell contact. Binding results in rapid differentiation of osteoclast precursors in bone marrow to mature osteoclasts and, at higher concentrations, in increased functional activity and reduced apoptosis of mature osteoclasts. The biological activity of OPG-L/ODF is neutralized by binding to osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF), a member of the TNF-receptor superfamily that also is secreted by osteoblast lineage cells. The biological importance of this system is underscored by the induction in mice of severe osteoporosis by targeted ablation of OPG/OCIF and by the induction of osteopetrosis by targeted ablation of OPG-L/ODF or overexpression of OPG/OCIF. Thus, osteoclast formation may be determined principally by the relative ratio of OPG-L/ODF to OPG/OCIF in the bone marrow microenvironment, and alterations in this ratio may be a major cause of bone loss in many metabolic disorders, including estrogen deficiency and glucocorticoid excess. That changes in but two downstream cytokines mediate the effects of large numbers of upstream hormones and cytokines suggests a regulatory mechanism for osteoclastogenesis of great efficiency and elegance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646108     DOI: 10.1359/jbmr.2000.15.1.2

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  219 in total

1.  RANKing the importance of measles virus in Paget's disease.

Authors:  F P Ross
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 2.  The mechanisms of estrogen regulation of bone resorption.

Authors:  B L Riggs
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  Regulation of osteoblast formation and function.

Authors:  J E Aubin
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 4.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

5.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

Authors:  M Neale Weitzmann; Cristiana Roggia; Gianluca Toraldo; Louise Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

6.  RANK ligand and the regulation of skeletal remodeling.

Authors:  Norman H Bell
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

7.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

Authors:  Guitty Eghbali-Fatourechi; Sundeep Khosla; Arunik Sanyal; William J Boyle; David L Lacey; B Lawrence Riggs
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

8.  Interactions between the immune system and bone.

Authors:  Patrizia D'Amelio; Giorgia Fornelli; Ilaria Roato; Giovanni Carlo Isaia
Journal:  World J Orthop       Date:  2011-03-18

9.  Genetic susceptibility to hip arthroplasty failure--association with the RANK/OPG pathway.

Authors:  M H A Malik; A Bayat; F Jury; W E R Ollier; P R Kay
Journal:  Int Orthop       Date:  2006-04-01       Impact factor: 3.075

10.  Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.

Authors:  Kristine M Erlandson; Maryann OʼRiordan; Danielle Labbato; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.